Frequency Therapeutics has appointed Steven Dworetzky as its senior vice president of molecular and cell biology research in a role that will see him work closely with its senior leadership team on scientific strategy and programme development.
Dworetzky (pictured) has held several senior roles for global pharmaceutical companies, such as senior principal scientist in the neuroscience department at Bristol-Myers Squibb and subsequently chief scientific officer and senior VP of discovery research at Knopp Biosciences.
He said: “Frequency’s PCA platform presents outstanding opportunities for the development of new medicines in indications with high unmet medical needs.
“I look forward to lending my experience and expertise to continue the work started by Bob Langer and Jeff Karp.”
Additionally, the US-based firm has promoted Raj Machanda to the role of chief development officer from his prior role as the senior VP of pharmaceutical development and technical operations.
Machanda will continue to lead development activities including formulation and analytical development, manufacturing and non-clinical safety studies to facilitate clinical trials and broaden the drug development pipeline.
Prior to joining the firm in 2016 Machanda held a number of leadership roles for the likes of Biogen, Avid Radiopharmaceuticals – which was acquired by Eli Lilly in 2010, PerkinElmer and Diatide.
David Lucchino, president, CEO and co-founder of Frequency Therapeutics, said: “I am very pleased to have a proven scientist and businessman like Steven lead the Frequency team in our Farrington, CT location.
“I am also honoured to announce the well-deserved promotion of Raj to chief development officer.
“Raj’s leadership has been critical in transforming Frequency to a highly efficient development stage organisation since joining us from Biogen.”